The largest community of pharma leaders

BIO: Trump’s Revenge on Pharma

The Trump administration unveiled a new drug price control policy, drawing opposition from pharma manufacturers and pharmacy benefit managers.

In unveiling a set of drug price control measures last week, the president displayed his bitterness that vaccine makers failed to announce their success in achieving high efficacy rates for new preventives before the Nov. 3 election. Instead of focusing on his administration’s remarkable achievement in financing and supporting record-breaking development of critical vaccines to combat COVID-19, President Trump lashed out at Pfizer for conspiring to delay the good news on its vaccine as part of a conspiracy to block his re-election.

Read More:


Recent Articles